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Summary Behc¸et’s disease is an inflammatory disease that can involve multiple systems. Here,
we describe a case of neuro-Behc¸et’s syndrome presenting with features mimicking acute
tuberculous meningitis. Behc¸et’s disease should be considered in the differential diagnosis of
a meningeal syndrome unless a viral or bacterial agent is demonstrated.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Behc¸et’s disease (BD) is a vasculitic disorder of unknown
etiology characterized by recurring episodes of oral and
genital ulcers, and panuveitis.1,2 Ocular, mucocutaneous,
articular, vascular, gastrointestinal and central nervous sys-
tem involvement can occur. Central nervous system involve-
ment occasionally presents with fever, headache and signs of
meningeal irritation, thus mimicking an acute meningeal
syndrome.2 Here, we report a patient who initially presented
with clinical features and laboratory findings suggestive of
acute bacterial meningitis, but was later diagnosed with
neuro-Behc¸et’s disease.* Corresponding author. Tel.: +90 3322236260;
fax: +90 332 2236181.
E-mail address: onururalmail@yahoo.com (O. Ural).
1201-9712/$36.00 # 2008 International Society for Infectious Diseases.
doi:10.1016/j.ijid.2008.08.004Case report
A 38-year-old female presented to the emergency depart-
ment with fever, headache, chills, nausea, vomiting and
altered mental status, which had developed over the
course of a few hours. On examination, her body tempera-
ture was 38.6 8C, her arterial blood pressure was 110/
75 mmHg and heart rate 115/min. She was confused and
had signs of meningeal irritation, suggesting an acute
meningeal syndrome. Whole blood analysis revealed a
leukocyte count of 13 600/mm3 (85% polymorphonuclear),
hemoglobin 11.8 g/dl, hematocrit 34% and platelet
count 310 000/mm3. Her erythrocyte sedimentation rate,
routine biochemistry and urine analysis were within normal
ranges. Anti-HIV antibodies, hepatitis B surface antigen,
hepatitis C virus antigen, rheumatoid factor, anti-nuclear
antibodies, anti-cardiolipin antibodies, anti-neutrophil
cytoplasmic antibodies and syphilis serology tests were
negative.Published by Elsevier Ltd. All rights reserved.
Figure 2 (A) Hypointense lesions in the brainstem on T1-
e142 O. Ural et al.Lumbar puncture revealed a high opening pressure,
although the pressure was not measured quantitatively, with
a hazy appearance of the cerebrospinal fluid (CSF). The CSF
contained 1089 cells/ml (90% neutrophils), 96 mg/dl protein,
42 mg/dl glucose (simultaneous blood glucose 108 mg/dl) and
118 mEq/l chloride. Gram staining of the CSF was negative.
The patient, who was diagnosed with acute bacterial menin-
gitis, transferred to the department of infectious diseases and
was started on ceftriaxone 4 g/day. CSF culture was found to
be negative. On the third day, with no clinical improvement
observed, the patient underwent a repeat lumbar puncture,
which revealed high CSF pressure with hazy fluid appearance.
The CSF contained 1265 cells/ml (75% lymphocyte), 88 mg/dl
protein, 39 mg/dl glucose (simultaneous blood glucose
145 mg/dl) and 120 mEq/l chloride. With no improvement in
clinical and CSF findings, ceftriaxone treatment was switched
to meropenem 6 g/day. On the fifth day of meropenem treat-
ment, still no improvement was observed. An MRI was ordered
and the lumbar puncture was repeated. Her cranial MRI
demonstrated tuberculomas in the basal cisterns (Figure 1).
Meropenem was stopped and the patient was started on iso-
niazid 300 mg/day, rifampicin 600 mg/day, streptomycin 1 g/
day, pyrazinamide 2 g/day and prednisolone 60 mg/day.
The CSF remained cloudy, with increased pressure, and
contained 275 cells/ml (60% lymphocyte), 36 mg/dl protein,
47 mg/dl glucose (simultaneous blood glucose 190 mg/dl) and
115 mEq/l chloride. The IgG index was elevated. No oligoclo-
nal IgG bandswere observed. Although therewas some degree
of improvement in the CSF findings, the CSF was found to be
negative for Ehrlich-Ziehl-Neelsen (EZN) staining on two occa-
sions and also for Mycobacterium tuberculosis RNA, raising
suspicion about the diagnosis of tuberculous meningitis.
The patient’s general condition worsened on the 5th day
of antituberculous therapy, which corresponds to the 12th
day of admittance to the hospital. Disorientation of time and
place was observed. A new MRI demonstrated (Figure 2)
hyperintense lesions in the pons on T2-weighted and FLAIR
sequences, with two lesions showing ring enhancement in the
pons anterior. The largest of the lesions was 7—8 mm, eachweighted sagittal MRI and (B) hyperintense lesion on T2-
weighted axial sequence.
Figure 1 Axial MRI showing two contrast-enhanced lesions in
the basal cisterns.surrounded by multiple nodules with punctate contrast
enhancement. When the patient’s past history was further
investigated for BD, she reported recurrent oral and genital
ulcerations. Further inquiry into the family history of the
patient revealed BD in three other members of the family.
Consultation with the ophthalmologist revealed uveitis. The
patient was found to be positive for the HLAB5 allele. She also
had a positive pathergy test. Neuropsychiatric examination
was remarkable for occasional crying fits and a mild left
hemihypoesthesia.
The patient, who was finally diagnosed with neuro-BD,
was transferred to the neurology department after antitu-
berculous therapy was stopped. She received intravenous
pulsed steroid therapy (1 g/day) for three days followed by
daily oral steroids plus a cyclophosphamide infusion given in
the rheumatology department. The patient was discharged
four weeks later with complete resolution of the CSF findings,
to be followed up by the neurology and rheumatology out-
patient departments. She continued to receive monthly
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prednisolone. No neurological relapse was observed during
the one-year follow-up.
Discussion
BD was named in 1937 after the Turkish dermatologist Hulusi
Behc¸et, who first described the triple-symptom complex of
this episodic vasculitis of unknown etiology.1,2 Criteria for
the diagnosis of BD, proposed in 1990 by the International
Study Group for Behc¸et’s Disease, must include oral
aphthous ulcerations observed by the physician or reported
reliably by the patient that recur at least three times in a 12-
month period, along with at least two of the following:
recurrent genital ulceration or scarring, skin lesions, ante-
rior uveitis, posterior uveitis or retinal vasculitis observed by
the ophthalmologist plus a positive pathergy test.3 These
criteria were reasonably fulfilled by our patient, who reli-
ably reported genital and oral aphthous ulcerations that
recurred more than three times a year, and had anterior
uveitis observed by the ophthalmologist and a positive
pathergy test. Patients with BD have a tendency towards
an association with HLAB51, with the association being
stronger in Turkey and Japan.4,5 Central nervous system
involvement in the disease is known as neuro-Behc¸et’s dis-
ease (n-BD) and occurs in 3.3—25% of BD cases, varying
according to different populations.1,6,7 Although our patient
had recurrent genital and oral aphthous ulcerations during
the previous five years, she did not seek medical attention
and hence remained undiagnosed until she was admitted to
hospital.
Neurological involvement in BD can be established in
two different patterns: parenchymal and non-parenchy-
mal. In parenchymal involvement, inflammation is primar-
ily within the nervous parenchyma, whereas in the
latter the main pathology is secondary to vascular compli-
cations within the nervous system. Parenchymal involve-
ment is the most frequently seen pattern and carries a
worse prognosis.1,2 In a large series by Akman-Demir et al.,
parenchymal involvement was seen in approximately 80%
of cases.6 Parenchymal neurological involvement in n-BD
usually presents with a brainstem syndrome.6—8 MRI is
currently the most sensitive imaging technique for studying
n-BD. In patients with parenchymal involvement, lesions
most commonly extend from brainstem to basal ganglia
unilaterally or bilaterally, appear hyperintense on T2-
weighted MRI and frequently demonstrate central contrast
enhancement.9
CSF analysis might assist the diagnosis of parenchymal n-
BD, showing increased protein and/or cell content. Despite
the fact that CSF pleocytosis is common, meningeal signs are
uncommon with parenchymal involvement.6 However, asep-
tic meningitis commonly exists with many parenchymal cen-
tral nervous system manifestations of n-BD, which might
cause fever, generalized headache and neck stiffness.10
The IgG index is usually elevated without oligoclonal band
positivity.1,7 Parenchymal involvement, increased MRI lesion
burden, CSF pleocytosis, primary or secondary progressive
course and frequent attacks are all associated with a poor
prognosis.6,8
Case series describing neurological involvement in BD
are limited in number.6,7,11 Meningitis is a relatively rareneurological complication of n-BD, occurring in 8% of
patients. In parenchymal disease, CSF pleocytosis together
with headache, fever and signs of meningeal irritation
might easily cause a misdiagnosis of bacterial meningitis.
Again, lack of CSF pleocytosis in the presence of meningeal
irritation might be misdiagnosed as aseptic meningitis.
However, aseptic meningitis was reported to be rare in
n-BD, being even rarer in the non-parenchymal type.2,6,7
Both parenchymal and non-parenchymal n-BD might
demonstrate CSF features with polymorphonuclear or lym-
phocytic pleocytosis. However, in cases of parenchymal n-
BD, neutrophilic and/or lymphocytic pleocytosis is usually
less than 100 cells/ml. The presence of more than 1000
cells/ml, as is the case with our patient, is unusual for n-
BD. In a large series, lymphocyte and neutrophil counts in
the CSF were reported to range between 0 and 485/ml, and
0 and 1100/ml, respectively.6 Indeed, increased protein
and/or cell content are the most frequent abnormalities in
parenchymal n-BD2,6, whereas fever and meningeal signs
were reported to be less common.6 In a study of 50 patients
by Kidd et al., four patients were reported to have menin-
gitis symptoms; two of these had parenchymal lesions and
two had normal MRIs.7 Siva et al. emphasized the impor-
tance of evaluating the inflammatory findings in the CSF
and parenchymal disease from the MRI, bearing in mind the
possibility that some cases reported to have been aseptic
meningitis might have been misclassified because of a lack
of sensitive imaging data.12
There has been no randomized, double-blind, placebo-
controlled trial of the treatment of patients with n-BD. To
date, treatment of n-BD remains largely empirical. Ster-
oids can be administered in pulsed or oral regimens during
the acute episode. Usually, corticosteroids have to be used
for years at a maintenance dose as patients can show
deterioration when the drug is decreased or stopped.1,9
Abrupt discontinuance of steroids might induce relapses
that show resistance to reinstitution of the treatment.13 In
patients fulfilling the criteria for poor prognosis or pre-
senting with a second neurological attack, steroids should
be combined with an immunosuppressant drug, preferably
azathioprine.6 Recently, the use of anti-tumor necrosis
factor-a (anti-TNF-a) was reported to be effective for
patients with refractory disease. TNF-a inhibition with
either infliximab or etanercept was successfully used in
patients who were poorly responsive to steroids and immu-
nosuppressants.14—16
Our case indicates that, although rare, parenchymal n-BD
can present as an acute meningeal syndrome mimicking
tuberculous meningitis. In patients suspected of having
tuberculous or drug-resistant meningitis, n-BD should also
be a concern.
Conflict of interest: No conflict of interest to declare.
References
1. Serdarog˘lu P. Behc¸et’s disease and the nervous system. J Neurol
1998;245:197—205.
2. Kara B, Somer A, Pis¸kin S, Aydınlı N, Salman N, Yalc¸ın I. Neuro-
Behc¸et syndrome presenting as acute meningeal syndrome. J
Infect 2006;52:120—3.
3. International Study Group for Behcet’s Diesease. Criteria for
diagnosis of Behcet’s disease. Lancet 1990;335:1078—80.
e144 O. Ural et al.4. Borlu M. Behc¸et Hastalıg˘ında etyopatogenez. J Health Sci
2007;16:63—72. [Etiopathogenesis of Behc¸et’s Disease].
5. Azizlerli G, Akdag˘ KA, Sarica R, Gu¨l A, Tutkun IT, Kulac¸ M, et al.
Prevalence of Behc¸et’s disease in Istanbul, Turkey. Int J Dermatol
2003;42:803—6.
6. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of
neurological involvement in Behcet’s disease: evaluation of
200 patients. Brain 1999;122:2171—81.
7. Kidd D, Steuer A, Denman AM, Rudge P. Neurological complica-
tions in Behc¸et’s syndrome. Brain 1999;122:2183—94.
8. Yesilot N, Gungor O, Baykan B, Eraksoy M, Serdaroglu P, Akman-
Demir G. Spinal cord involvement in neuro-Behcet’s disease. J
Neurol 2002;249(Suppl 1):I/161.
9. Coban O, Bahar S, Akman-Demir G, Tas¸ci B, Yazici H, Serdarog˘lu
P. Masked assessment of MRI findings: is it possible to differenti-
ate neuro-Behcet’s disease from other central nervous system
diseases? Neuroradiology 1999;41:255—60.
10. Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behc¸et’s
disease. A review. Neurologist 2005;11:80—9.11. Serdaroglu P, Yazici H, O¨zdemir C, Yurdakul S, Bahar S, Aktin E.
Neurological involvement in Behc¸et’s syndrome: a prospective
study. Arch Neurol 1989;46:265—9.
12. Siva A, Kantarci OH, Saip S, Altintas¸ A, Hamuryudan V, Islak C,
et al. Behcet’s disease: diagnostic and prognostic aspects of
neurological involvement. J Neurol 2001;248:65—103.
13. Yazici H, Yurdakul S, Hamuryudan V. The management of Beh-
cet’s syndrome: how are we doing? Clin Exp Rheumatol 1999;17:
145—7.
14. Sarwar H, McGrath Jr H, Espinosa LR. Successful treatment of
long-standing neuro-Behc¸et’s disease with infliximab. J Rheu-
matol 2005;32:181—3.
15. Ribi C, Sztajzel R, Delawelle J, Chizzolini C. Efficacy of TNF
(alpha) blockade in cyclophosphamide resistant neuro-Behc¸et
disease. J Neurol Neurosurg Psychiatry 2005;76:1733—5.
16. Alty JE, Monaghan TM, Bamford JM. A patient with neuro-
Behc¸et’s disease is successfully treated with etanercept: further
evidence for the value of TNF-alpha blockade. Clin Neurol
Neurosurg 2007;109:279—81.
